Study for Tolerability of abT-Cell Therapy in Patients Refractory to Immune Checkpoint Inhibitors - Tolerability of abT-Cell Therapy in Patients Refractory to ICIs

Takimoto Rishu0 个研究点目标入组 30 人开始时间: 2022年8月23日最近更新: 2024年5月27日

适应症

试验速览

暂无简介。

•(1) BSC determined to have PD based on imaging findings after at least 3 months of ICIs.
•(2) Receive abT cells within 30 to 120 days of last administration of ICIs.
•(3) Have an Eastern Cooperative Oncology Group performance-status score of 0 or 1.
•(4) Be at age 18 or older.
•(5) Visit outpatient department on schedule.
•(6) Have an adequate function of liver, kidney, and bone marrow when the eligibility is confirmed.
•(7) Provide agreement of the attending doctor to participate in this study.
•(8) Provide written consent to participate this study.

•(1) Be symptomatic pulmonary fibrosis or interstitial pneumonia, or with a predisposition or history of such disease.
•(2) Have a history of serious adverse events with treatment with ICIs
•(3) Have a history of a serious drug allergy.
•(4) Be HIV or HTLV-1 positive.
•(5) Have a serious cardiac disorder.
•(6) Patients who have previously treated allogenic transplantation.
•(7) Have an active autoimmune disease.
•(8) Have a concurrent cancer.
•(9) Have an infectious disorder that is difficult to control.
•(10) Be a female who is pregnant, nursing, or of childbearing potential.
•(11) Be determined to be inappropriate by the doctor in charge.

发起方

Takimoto Rishu